Alnylam Publishes Results from Phase II GEMINI Trial with ALN-RSV01

Source: Alnylam Pharmaceuticals (press release). Share |. Subscribe to a free copy of our daily. Nanowerk Nanotechnology News Email Digest. with a compilation of all of the day's news. ...

Press Releases: Nanotechnology Stocks update for Investors …

The Accelrys Nanotechnology Consortium has delivered a range of cutting-edge software tools to meet the challenges of rational nanodesign. Following a very successful Phase I, supported by over 30 members worldwide, Phase II is now ...

Tuning In To Multispectral and Polarimetric Target Detection (SpaceDaily)

by Mr. John Scheihing Wright-Patterson AFB OH (AFNS) Feb 09, 2010 Having completed Phase I of a Small Business Innovation Research effort ultimately pursuing a full-scale sensor capability available for ready integration into small unmanned aerial systems sensor suites, Applied NanoFemto Technologies has begun SBIR Phase II work on the heretofore highly successful endeavor.

Nanotechnology Now – Press Release: "Abraxis BioScience Confirms …

Governor Rendell: $5.7 Million Investment in Nanotechnology Will Build Upon Research, Commercialization Efforts January 29th, 2010. NASA selects DNA Medicine Institute's Nanoscale Diagnostics Technology for Phase II SBIR January 29th, ...

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes (News-Medical-Net)

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments ...